Clinical Trial Update: Comparison of Post-Inflammatory Pigment Alteration After Psoriasis Treatment (PIPA - Dermavant) [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/Phase 3 clinical trial evaluating post-inflammatory pigment alteration after psoriasis treatment (PIPA) involving Dermavant; enrollment is by invitati…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• PIPA

Snippet

Sponsor: Wake Forest University Health Sciences | Conditions: ICD10 Code L40.9 for Psoriasis | Phase 2, Phase 3 | Status: ENROLLING_BY_INVITATION